18F-Fluorocholine PET/CT in Medullary Thyroid Cancer

Medullary Thyroid Cancer Clinical Trial

Official title:

Diagnostic Value of 18F-Fluorocholine PET/CT for the Detection of Medullary Thyroid Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03643055
• Other study ID #: 92/08/14
• Status: Active, not recruiting
• Start date: September 3, 2014
• Est. completion date: September 3, 2024

Study information

• Verified date: November 2020
• Source: University Medical Centre Ljubljana
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To assess the diagnostic accuracy of 18F-Fluorocholine PET/CT for the detection of medullary thyroid cancer in patients with primary and recurrent disease.

Description:

Medullary thyroid cancer (MTC) is a relatively rare type of cancer that represents up to 10% of all primary thyroid cancers. It is a neuroendocrine tumour derived from parafollicular C-cells of the thyroid. It occurs either sporadically or in a hereditary form as a component of the type 2 multiple endocrine neoplasia (MEN) syndromes, MEN2A and MEN2B, and the related syndrome, familial MTC (FMTC).

Currently, the diagnosis of MTC is suspected based on the results of fine-needle aspiration (FNA) cytology, immunohistochemical analysis and elevated laboratory values of tumour markers calcitonin (Ctn) and carcinoembryonic antigen (CEA). According to the 2015 ATA guidelines, the preoperative imaging workup in all patients should include ultrasound examination of the neck; in selected patients, contrast-enhanced CT of the neck and chest, three-phase contrast-enhanced multi-detector liver CT, or contrast-enhanced MRI of the liver, and axial MRI and bone scintigraphy is also recommended. The curative therapy of choice is surgical removal of the tumour and/or metastases.

Nodal metastases are detected in 35-50% and distal metastases in about 15% of patients with primary MTC. Even with currently recommended diagnostic imaging techniques, about 50% of patients have persistent/recurrent disease after surgical treatment. This implies that currently available diagnostic imaging studies are suboptimal for accurate disease staging. New hybrid molecular imaging techniques based on SPECT/CT and especially PET/CT could improve disease detection by visualising pathophysiological processes in vivo. The most studied PET radiopharmaceutical for MTC imaging to date has been 18F-FDOPA, with recent studies focusing also on somatostatin receptor imaging using 68Ga-DOTATATE/TOC/NOC radiotracers.

18F-fluorocholine is a structural analogue of choline. It accumulates in cells with active membrane synthesis and overexpressed intracellular signal transduction, processes that are overactive in benign and malignant neoplasms. 18F-fluorocholine is currently primarily used for prostate cancer imaging. In contrast to radiotracers such as18F-fluorodeoxyglucose (18F-FDG), it is also taken up by well-differentiated neoplasms in which 18F-FDG uptake is unreliable. Similarly to 18F-FDG, 18F-fluorocholine is also known to accumulate in inflamed and infected tissue. However, this limitation could be overcome by performing multi-time-point imaging and using basic kinetic analysis. The working hypothesis is that 18F-fluorocholine might be efficiently taken up by primary MTC tumour as well as loco-regional and distant metastases.

The aim of the trial is to investigate the diagnostic accuracy of 18F-fluorocholine PET/CT in comparison to existing imaging modalities (US, CT and MRI).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: September 3, 2024
• Est. primary completion date: March 3, 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with medullary thyroid cancer (sporadic or hereditary form).

• Patients with newly diagnosed MTC for primary staging (based on fine needle aspiration cytology results).

• Patients with suspicion of MTC recurrence for re-staging (based on biochemical, conventional imaging or clinical examination).

• Patients with metastatic MTC on systemic therapy for disease activity assessment.

Exclusion Criteria:

• Pregnancy.

• Patient with any PET/CT-scan exam contraindication (eg. severe claustrophobia).

Related Conditions & MeSH terms

• Carcinoma, Neuroendocrine
• Medullary Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Diagnostic Test:
• 18F-fluorocholine PET/CT
18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.

Locations

Country	Name	City	State
Slovenia	Department for nuclear medicine, University medical centre Ljubljana	Ljubljana

Sponsors (2)

Lead Sponsor	Collaborator
University Medical Centre Ljubljana	Institute of Oncology Ljubljana

Country where clinical trial is conducted

Slovenia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy in primary medullary thyroid cancer	Ability to detect primary medullary thyroid cancer (primary, nodal and metastatic lesions) in correlation with histopathological and/or conventional imaging data.	1 month
Primary	Sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy in recurrent medullary thyroid cancer	Ability to detect recurrent medullary thyroid cancer (nodal and distant metastatic lesions) in correlation with histopathological and/or conventional imaging data.	3 months
Secondary	Survival analysis based on the initial PET/CT examination	Survival analysis of the time to disease progression or disease recurrence after the initial PET/CT examination.	5 years
Secondary	Biochemical/clinical outcome - Ctn levels	Normalization/stable elevation/increasing levels of serum Ctn.	5 years
Secondary	Biochemical/clinical outcome - CEA levels	Normalization/stable elevation/increasing levels of serum CEA.	5 years
Secondary	Correlation between tumour metabolic activity and biochemical and histological markers	Correlation of tumour metabolic activity with biochemical serum marker levels (Ctn, CEA) and tumour metabolic activity and histological quantitative indexes (eg Ki-67).	1 month
Secondary	Modification rate of patient's surgical and medical care after 18F-fluorocholine PET/CT	Rate of patients whose management was modified based on the PET/CT imaging findings.	5 years
Secondary	Basic kinetic analysis of metabolic activity in the primary tumour, nodal and distant metastases.	Ability to differentiate benign and malignant lesions using multiple-time-point imaging.	3 months